Frederick Baehner
Overview
Explore the profile of Frederick Baehner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu S, Erazo T, Jee J, Arfe A, Gupta A, Pike L, et al.
Eur J Cancer
. 2024 Aug;
210:114257.
PMID: 39151324
Introduction: No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting....
2.
Abel M, Shui A, Jo Chien A, Rugo H, Melisko M, Baehner F, et al.
Ann Surg Oncol
. 2022 Jul;
29(12):7739-7747.
PMID: 35810223
Objective: The aim of this study was to evaluate whether patients with invasive lobular carcinoma (ILC) are more likely to have discordant clinical and genomic risk than those with invasive...
3.
Nitz U, Gluz O, Kummel S, Christgen M, Braun M, Aktas B, et al.
J Clin Oncol
. 2022 Apr;
40(23):2557-2567.
PMID: 35404683
Purpose: To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine...
4.
Christgen M, Gluz O, Harbeck N, Kates R, Raap M, Christgen H, et al.
Cancer
. 2020 Aug;
126(22):4847-4858.
PMID: 32780421
Background: Invasive lobular breast cancer (BC) is the second most common BC subtype. Prognostic parameters (tumor classification, lymph node status, histologic grade, Oncotype DX recurrence score [RS], progesterone receptor status,...
5.
Woodward W, Barlow W, Jagsi R, Buchholz T, Shak S, Baehner F, et al.
JAMA Oncol
. 2020 Jan;
6(4):505-511.
PMID: 31917424
Importance: The 21-gene assay recurrence score is increasingly used to personalize treatment recommendations for systemic therapy in postmenopausal women with estrogen receptor (ER)- or progesterone receptor (PR)-positive, node-positive breast cancer;...
6.
Perez E, Ballman K, Mashadi-Hossein A, Tenner K, Kachergus J, Norton N, et al.
J Natl Cancer Inst
. 2016 Oct;
109(2).
PMID: 27794124
Background: Genomic data from human epidermal growth factor receptor 2-positive (HER2+) tumors were analyzed to assess the association between intrinsic subtype and clinical outcome in a large, well-annotated patient cohort....
7.
Campbell M, Baehner F, OMeara T, Ojukwu E, Han B, Mukhtar R, et al.
Breast Cancer Res Treat
. 2016 Oct;
161(1):17-28.
PMID: 27785654
Purpose: The recent increase in the incidence of ductal carcinoma in situ (DCIS) has sparked debate over the classification and treatment of this disease. Although DCIS is considered a precursor...
8.
Campbell M, Wolf D, Mukhtar R, Tandon V, Yau C, Au A, et al.
PLoS One
. 2013 Nov;
8(10):e79114.
PMID: 24205370
Tumor associated macrophages (TAMs) are recruited from the circulation to the tumor site, and can undergo a spectrum of phenotypic changes, with two contrasting activation states described in the literature:...
9.
Nejadnik H, Henning T, Do T, Sutton E, Baehner F, Horvai A, et al.
PLoS One
. 2012 Dec;
7(12):e49971.
PMID: 23251354
Objectives: The purpose of our study was to assess the chondrogenic potential and the MR signal effects of GadofluorineM-Cy labeled matrix associated stem cell implants (MASI) in pig knee specimen....
10.
Petrillo L, Wolf D, Kapoun A, Wang N, Barczak A, Xiao Y, et al.
Breast Cancer Res Treat
. 2012 Sep;
135(3):913-22.
PMID: 22941572
Though xenografts are used extensively for drug development in breast cancer, how well xenografts reflect the breadth of primary breast tumor subtypes has not been well characterized. Moreover, few studies...